Compare Crispr Therapeutics AG (CRSP) vs Diamondback Energy Inc (FANG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Diamondback Energy Inc — how do they compare? Crispr Therapeutics AG trades at $51.28 (market cap $4.97B), while Diamondback Energy Inc trades at $189.76 (market cap $53.64B). The key difference: Diamondback Energy Inc is far larger — about 10.8× Crispr Therapeutics AG's market cap, and Diamondback Energy Inc pays a 2.31% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | FANG | |
|---|---|---|
Market Cap | $4.97B | $53.64B |
Sector | Health | Energy |
52-Week High | $76.78 | $213.69 |
52-Week Low | $44.34 | $134.53 |
Enterprise Value | $3.32B | $67.37B |
Dividend Yield | — | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Diamondback Energy (FANG) trades at $191.6, up 4.48% today, with a bullish technical signal and strong analyst support. The stock shows robust revenue growth, reaching $14.93B in 2025, though net income margins have compressed. Recent earnings beat expectations in Q1 2026, and the company maintains a solid balance sheet with manageable debt levels. A dividend of $1.10 was recently paid, enhancing shareholder returns.
FANG presents a favorable outlook with a consensus price target of $234.50, implying significant upside. However, risks include volatile oil prices, declining profit margins, and execution challenges in a competitive energy sector. The stock's high P/E ratio of 195.51 warrants caution, but strong cash flow and institutional bullishness support a positive investment case for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →
